Tobramycin Inhalation powder: an Efficient and Efficacious Therapy for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis

References

• Ratjen F . Update in cystic fibrosis 2008. Am. J. Respir. Crit. Care Med.179, 445–448 (2009).
   PubMed Web of Science ®Google Scholar
• Dequeker E Stuhrmann M Morris MA et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders–updated European recommendations. Eur. J. Hum. Genet.17, 51–65 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenstein B Zeitlin PL . Cystic fibrosis. Lancet35 (9098), 277–282 (1998).
   Google Scholar
• Flume P . Pulmonary complications of cystic fibrosis. Respir. Care54 (5), 618–627 (2009).
   PubMed Web of Science ®Google Scholar
• Gibson R Burns JL Ramsey BW . Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med.168, 918–951 (2003).
   PubMed Web of Science ®Google Scholar
• Lambiase A Raia V Del Pezzo M Sepe A Carnovale V Rossano F . Microbiology of airwary disease in a cohort of patients with cystic fibrosis. BMC Infect. Dis.6 (4), (2006).
   PubMedGoogle Scholar
• Razvi S Quittel L Sewall A Quinton H Marshall B Saiman L . Respiratory microbiology of patients with cystic fibrosis in the United States. Chest136 (6), 1554–1560 (2009).
   PubMed Web of Science ®Google Scholar
• Li Z Kosorok MR Farrel PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. J. Pediatr.138, 699–704 (2005).
   Google Scholar
• Hoiby N . Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med.9 (32), doi:10.1186/1741-7015-9-32 (2011).
   PubMedGoogle Scholar
• Poole K . Pseudomonas aeruginosa: resistance to the max. Front. Microbiol.2 (65), doi:10.3389/fmicb.2011.00065 (2011).
   PubMedGoogle Scholar
• UK Cystic Fibrosis Trust Antibiotic Working Group . Antibiotic Treatment for Cystic Fibrosis (3rd Edition).UK Cystic Fibrosis Trust, London (2009).
   Google Scholar
• Cystic Fibrosis Foundation Patient Registry . 2012 annual data report. Cystic Fibrosis Foundation ; Bethesda, MD, USA (2012). www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf.
   Google Scholar
• Mogayzel P Naureckas ET Robinson KA et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med.187 (7), 680–689 (2013).
   PubMed Web of Science ®Google Scholar
• Smyth A Bell SC Bojcin S et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J. Cyst. Fibros.13, 823–842 (2014).
   Web of Science ®Google Scholar
• Al-Aloul M Miller H Alapati S Stockton PA Ledson MJ Walshaw MJ . Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol.39, 15–20 (2005).
   PubMed Web of Science ®Google Scholar
• Elborn J Prescott RJ Stack BH et al. Elective versus symptomatic antibiotic treatment in antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax55 (5), 355–358 (2000).
   PubMed Web of Science ®Google Scholar
• Di Sant'agnese P . Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am. J. Dis. Child.72, 17–61 (1946).
   Google Scholar
• Geller D . Aerosol antibiotics in cystic fibrosis. Respir. Care.54 (5), 658–669 (2009).
   PubMed Web of Science ®Google Scholar
• Lipuma J . M.icrobiological and immunologic considerations with aerosolized drug delivery. Chest120, 118S–123S (2001).
   PubMed Web of Science ®Google Scholar
• Pressler T Assael B Fischer R et al. In vitro susceptibility to Pseudomonas aeruginosa does not predict clinical response to AZLI: a responder analysis in subjects with CF. J. Cyst. Fibros.10, S27 Abstract 107 (2011).
   Google Scholar
• Kuhn R . Formulation of aerosolized therapeutics. Chest120, 94S–98S (2001).
   PubMed Web of Science ®Google Scholar
• Ramsey B Pepe MS Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis, Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med.340, 23–30 (1999).
   PubMed Web of Science ®Google Scholar
• Parkins M Elborn JS . Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J. Antimicrob. Chemother.65, 1853–1861 (2010).
   PubMed Web of Science ®Google Scholar
• Boucher H Talbot GH Bradley JS et al. Bad bugs, no drugs: no ESKAPE! Clin. Infect. Dis. 48, 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Tappenden P Harnan S Uttley L et al. The cost–effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. Presented at : ISPOR 16th Annual European Congress.16 (7), A372, Dublin, Ireland, 2–6 November 2013.
   Google Scholar
• Smith A . Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?J. Cyst. Fibros.1, 189–193 (2002).
   PubMedGoogle Scholar
• Stephens D Garey N Isles A Levison H Gold R . Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr. Infect. Dis.2 (3), 209–211 (1983).
   PubMedGoogle Scholar
• Cheer Sm Waugh J Noble S . Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs63, 2501–2520 (2003).
   PubMed Web of Science ®Google Scholar
• Ratjen F Rietschel E Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother.57, 306–311 (2006).
   PubMed Web of Science ®Google Scholar
• Schuster A Haliburn C Doring G Goldman, Mh . Freedom Study, Group: safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax68 (4), 344–350 (2013).
   PubMed Web of Science ®Google Scholar
• Mccoy K Quittner AL Oermann CM Gibson RL Retsch-Bogart GZ Montgomery AB . Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med.178, 921–928 (2008).
   PubMed Web of Science ®Google Scholar
• Assael B Pressler T Bilton D et al. Inhaled aztreonam lysine vs inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J. Cyst. Fibros.12, 130–140 (2013).
   PubMed Web of Science ®Google Scholar
• Stass H Nagelschmitz J Willmann S et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin. Drug Investig.33 (6), 419–427 (2013).
   PubMed Web of Science ®Google Scholar
• Sabet M Miller CE Nolan TG et al. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infections due to Pseudomonas aeruginosa. Antimicrob. Chemother.53 (9), 3923–3928 (2009).
   PubMed Web of Science ®Google Scholar
• Geller D Flume PA Staab D et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med.183 (11), 1510–1516 (2011).
   PubMed Web of Science ®Google Scholar
• Clancy J Dupont L Konstan MW et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax.68 (9), 818–825 (2013).
   PubMed Web of Science ®Google Scholar
• Bilton D Pressler T Fajac I et al. Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. Presented at : European Cystic Fibrosis Conference.Gothenburg, Sweden, 11–14 June 2014.
   Google Scholar
• Bilton D Pressler T Fajac I et al. Phase 3 efficacy and safety data from randomized, multicentre study of liposomal amikacin for inhalation (Arikace) compared with TOBI in Cystic Fibrosis patients with chronic infection due to Pseudomonas aeruginosa. Presented at : North American Cystic Fibrosis Conference.Salt Lake City, UT, USA, 17–19 October 2013.
   Google Scholar
• Thompson R Presti EA . Nebramycin, a new broad spectrum antibiotic complex. I. Detection and biosynthesis. Antimicrob. Agents. Chemother.7, 332–340 (1967).
   PubMedGoogle Scholar
• Lynch S Puglisis Jd . Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J. Mol. Biol.306 (5), 1037–1058 (2001).
   PubMed Web of Science ®Google Scholar
• Taber H Mueller JP Miller PF Arrow AS . Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev.51 (4), 439–457 (1987).
   PubMedGoogle Scholar
• Kapusnik J Hackbarth CJ Chambers HF Carpenter T Sande MA . Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J. Infect. Dis.158 (1), 7–12 (1988).
   PubMed Web of Science ®Google Scholar
• Fraud S Poole K . Oxidative stress induction of the MexXY multi-drug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa. Antimicrob. Agents. Chemother.55, 1068–1074 (2011).
   PubMed Web of Science ®Google Scholar
• Macleod D Nelson LE Shawar RM et al. Aminoglycoside resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term intermittent, inhaled tobramycin treatment. J. Infect. Dis.181, 1180–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Hunt B Weber A Berger A Ramsey B Smith AL . Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother.39, 34–39 (1995).
   PubMed Web of Science ®Google Scholar
• Heijerman H Westerman E Conway S et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European concensus. J. Cyst. Fibros.8 (5), 295–315 (2009).
   PubMed Web of Science ®Google Scholar
• Geller D Konstan MW Smith J Noonberg Sb Conrad C . Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol.42 (4), 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• Geller D Weers J Heuerding S . Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol. Med. Pulm. Drug Deliv.24 (4), 175–182 (2011).
   PubMed Web of Science ®Google Scholar
• Weers J Tarara T . The PulmoSphere platform for pulmonary drug delivery. Ther. Deliv.5, 277–295 (2014).
   PubMedGoogle Scholar
• Nasr S Nick J Ezzet N et al. Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial. Presented at : 27th Annual North American Cystic Fibrosis Conference.Salt Lake City, UT, USA, 17–19 October 2013 ( Abstract).
   Google Scholar
• Vandevanter D Geller DE . Tobramycin administered by the TOBI® Podhaler ® for persons with cystic fibrosis: a review. Med. Dev. (Auckland)4, 179–188 (2011).
   PubMedGoogle Scholar
• Tiddens H Geller DE Challoner P et al. Effects of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol. Med.19 (4), 456–465 (2006).
   PubMedGoogle Scholar
• Haynes A Ament B Heng C et al. In vitro aerosol delivery performance of tobramycin powder for inhalation (TOBI Podhaler) using inspiratory flow profiles from cystic fibrosis patients. Presented at : North American Cystic Fibrosis Conference. Salt Lake City, UT, USA, 17–19 October 2013 ( Poster).
   Google Scholar
• Pavkov R Geller DE Ament B Heuerding S Gupta A . Dynamic inspiratory flow characteristics through the T-326 dry powder inhaler in cystic fibrosis patients. RDD Europe2, 325–328 (2013).
   Google Scholar
• Geller D Ament B Heuerding S Maykut R Pavkov R . Inspiratory flow characteristics of the T-326 dry powder inhaler (DPI) in CF patients. J. Cyst. Fibros.12 (Suppl.1), S66 (2013).
   Google Scholar
• TOBI® Podhaler Product Monograph . Novartis Pharmaceuticals Canada Inc. Dorval, Quebec, (2013).
   Google Scholar
• Newhouse M Hirst PH Duddu SP et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest124 (1), 360–366 (2003).
   PubMed Web of Science ®Google Scholar
• Konstan M Flume PA Kappler M et al. Safety, efficacy and convenience of tobramycin inhaled powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros.10, 54–61 (2011).
   PubMed Web of Science ®Google Scholar
• Konstan M Geller De Minic P Brockhaus F Zhang J Angyalosi G . Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr. Pulmonol.46 (3), 230–238 (2011).
   PubMed Web of Science ®Google Scholar
• Galeva I Konstan MW Higgins M et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr. Med. Res. Opin.29 (8), 947–956 (2013).
   PubMed Web of Science ®Google Scholar
• TOBI Podhaler 28 mg inhalation powder, hard capsules. Summary of product characteristics. www.google.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0CCMQFjAB&url=http%3A%2F%2Fwww.ask.novartispharma.ca%2Fdownload.htm%3Fres%3Dtobi%2520podhaler_scrip_e.pdf%26resTitleId%3D799&ei=hW7AVJmtKsvjsAT6uIHoDg&usg=AFQjCNHMUIqY3akFFs0SVee0hiIddTkfMw&sig2=wUxhsf3PWb47T58c6BxOkg.
   Google Scholar
• Konstan M Flume PA Wan R et al. Long term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the EDIT trial and its two open-label extension studies. Presented at : 27th Annual North American Cystic Fibrosis Conference. Salt Lake City, UT, USA, 17–19 October 2013 ( Abstract).
   Google Scholar
• Geller D Nasr SZ Piggott S He E Angyalosi G Higgins M . Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir. Care59 (3), 388–398 (2014).
   PubMed Web of Science ®Google Scholar
• Konstan M Parkins MD Angyalosi G Higgins M . Tobramycin inhaltion powder is as effective as Tobramycin inhalation solution in patients with cystic fibrosis: a subgroup analysis of the EAGER trial. Presented at : American Thoracic Society. San Diego, CA, USA, 16–21 May, 2014.
   Google Scholar
• Foweraker J Laughton CR Brown DF Bilton D . Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob. Agents Chemother.53, 4809–4815 (2009).
   PubMed Web of Science ®Google Scholar
• Workentine M Sibley CD Glezerson B et al. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE8, e60225 (2013).
   PubMed Web of Science ®Google Scholar
• Harrison M Mccarthy M Fleming C et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J. Cyst. Fibros.13 (6), 692–8 (2014).
   PubMed Web of Science ®Google Scholar
• Brown C Nash EF Camerson S Rashid R Whitehouse JL . Clinical outcomes and patient satisfaction following initation of the TOBI podhaler in CF adults. J. Cyst. Fibros.12 (Suppl. 1), S65 (2013).
   Google Scholar
• Nash E Ahitan B Brown C Rashid R Whitehouse JL . Comparison of pharamacy presecription refill frequency in CF adults before and after switching from tobramycin inhalation solution (TIS) to TOBI podhaler–‘real world’ evidence of improved adherence. J. Cyst. Fibros.12s265 (2013).
   Google Scholar
• Nick J Moskowitz SM Chmiel JF et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann. Am. Thorac Soc.11 (3), 342–350 (2013).
   Google Scholar
• Nichols D Caceres S Caverly L et al. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J. Surg. Res.13, 767–776 (2013).
   Google Scholar
• Saiman L Chen Y San Gabriel P Knirsch C . Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xyloxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother.46 (4), 1105–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Kahlmeter G Dahlager JI . Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J. Antimicrob. Chemother.13 (Suppl. A), 9–22 (1984).
   PubMed Web of Science ®Google Scholar
• Hoffmann I Rubin BK Iskandar SS et al. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr. Pulmonol.34, 375–377 (2002).
   PubMed Web of Science ®Google Scholar
• Patatanian L . Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr. Infect. Dis.25 (3), 276–278 (2006).
   Google Scholar
• Sawicki G Sellers D Robinson WM . High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J. Cyst. Fibros.8, 91–96 (2009).
   PubMed Web of Science ®Google Scholar
• Ziaian T Sawyer MG Reynolds KE et al. Treatment burden and health-related quality of life in children with diabetes, cystic fibrosis, and asthma. J. Pediatr. Child Health42 (10), 596–600 (2006).
   Google Scholar
• Quittner A Modi AC Lemanek KL Ievers-Landis CE Rapoff MA . Evidence-based assessment of adherence to medical treatments in pediatric psychology. J. Pediatr. Psychol.33 (9), 916–938 (2008).
   PubMed Web of Science ®Google Scholar
• Parkins M Rendall JC Elborn JS . Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest66 (8), 680–685 (2012).
   Google Scholar
• Nikolaizik W Vietzke D Ratjen F . A pilot study to compare tobramcin 80mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Can. Respir. J.15, 259–262 (2008).
   PubMed Web of Science ®Google Scholar
• Govoni M Poli G Acerbi D et al. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) and PARI LC Plus® nebulisers in cystic fibrosis patients. Pulm. Pharmacol. Ther.26, 249–255 (2013).
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart G Burns JL Otto KL et al. Azli Phase Ii Study Group.: a phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol.43, 47–58 (2008).
   PubMed Web of Science ®Google Scholar
• Galeva I Konstan MW Higgins M Angyalosi G Brockhaus F Thomas K Chuchalin AG . A challenging double-blind, placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial. Presented at : 35th European Cystic Fibrosis Conference. Dublin, Ireland, 11, s126–9 June 2012.
   Google Scholar
• Quittner A Higgins M Angyalosi G Brockhaus F Thomas K Zhang J . Trends in health-related quality of life (HRQoL) in cystic fibrosis with tobramycin inhalation powder: The EDIT trial. Presented at : 35th European Cystic Fibrosis Conference. Dublin, Ireland. 11, s736–9 June 2012.
   Google Scholar
• Cystic fibrosis foundation. www.cff.org/treatments/Pipeline/ ( last updated June 2014).
   Google Scholar
• Parkins MD Elborn JS . Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev. Respir. Med.5 (5), 1–14 (2011).
   PubMed Web of Science ®Google Scholar